The Board refers to its earlier decision regarding the duration of Phase 1 of the Affordable Medicines Facility - malaria ("AMFm") (GF/B22/DP13) and notes that Phase 1 will end on 31 December 2012.
The Board recognizes the importance of an orderly transition for those countries that are part of the Phase 1 pilot following its decision expected in November 2012 on whether to expand, accelerate, modify, terminate or suspend the AMFm business line. In order to support an orderly transition towards implementing the outcome of the November decision, the Global Fund will continue to host AMFm during a twelve-month transition period, and the Board will approve the details of the transition in November.
In order to support the transition period, the capacity of the Global Fund Secretariat to manage the activities of the AMFm shall be extended by twelve months (until 31 December 2013). The Board requests that the Secretariat include the appropriate budgetary implications of the extended mandate of the AMFm in the 2013 Operating Expenses Budget.
The incremental budgetary implications of this decision point for the 2013 Operating Expenses Budget amount to approximately US$2.5 million to allow the Secretariat to support an orderly transition following the Board’s expected decision in November 2012.